Total EDAP revenue up 20.4% year-over-year in the first six months of 2016 Continued growth in HIFU system sales and treatment-driven revenue with strong margins Focal One® 510k under FDA review Solid cash position at €21.9 million as of June 30, 2016 LYON, France , Aug.
LYON, France , Sept. 06, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Marc Oczachowski , Chief Executive Officer of EDAP TMS , is scheduled to present at the 18 th Annual Rodman & Renshaw Global Investment Conference being
LYON, France , Sept. 12, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the signature of a contract for the installation of Ablatherm Robotic HIFU at the renowned Duke University Hospital located in Durham, North Carolina .
LYON, France , Oct. 11, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the results of a multicentric study using Ablatherm Robotic HIFU which demonstrates promising oncologic outcomes with low side effects.
Highlights at the end of September 30, 2016 : Total cumulated revenue in 2016 up 22% year-over-year; Driven by HIFU growth, Gross Margin increases to 45%; 111% growth in HIFU revenues in Q3 of 2016 compared to Q3 2015; Company continues to show operating profit in 2016 at the end of Q3; Strong
LYON, France , Dec. 08, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the award of the prestigious 2016 Prix Galien, in the Medical Device category, for its Focal One HIFU device dedicated to the treatment of localized prostate
LYON, France , Dec. 12, 2016 (GLOBE NEWSWIRE) -- EDAP TMS S.A. (NASDAQ:EDAP), the global leader in therapeutic ultrasound today announced that it has retained CG Capital , a leading capital markets development and research firm as their new investor relations counsel.
